A. J. Arribas

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

This study evaluates lisavanbulin's anti-lymphoma activity and EB1 expression in DLBCL, showing potent in vitro cytotoxicity and potential clinical relevance.

This paper develops EG-011, a first-in-class WASp activator with anti-tumor activity in hematological cancers, including resistant models.

This study uses ex vivo drug sensitivity testing to identify treatment responses and vulnerabilities in chronic lymphocytic leukemia patients, showing that pan-PI3Ki and combinations with venetoclax can be effective in idelalisib-refractory/intolerant cases.

This study shows that IL-1α from subcapsular sinus macrophages promotes melanoma metastasis by enhancing STAT3 signaling in tumor cells, and blocking this pathway reduces metastasis.